Trinity Biotech (TRIB) Equity Average (2021 - 2025)
Historic Equity Average for Trinity Biotech (TRIB) over the last 5 years, with Q2 2025 value amounting to -$42.4 million.
- Trinity Biotech's Equity Average fell 6211.99% to -$42.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$42.4 million, marking a year-over-year decrease of 6211.99%. This contributed to the annual value of -$29.6 million for FY2024, which is 12633.49% down from last year.
- Per Trinity Biotech's latest filing, its Equity Average stood at -$42.4 million for Q2 2025, which was down 6211.99% from -$30.8 million recorded in Q4 2024.
- Over the past 5 years, Trinity Biotech's Equity Average peaked at $11.2 million during Q3 2022, and registered a low of -$42.4 million during Q2 2025.
- Over the past 5 years, Trinity Biotech's median Equity Average value was -$4.4 million (recorded in 2023), while the average stood at -$10.9 million.
- Its Equity Average has fluctuated over the past 5 years, first soared by 705031.85% in 2022, then plummeted by 102968.36% in 2023.
- Over the past 5 years, Trinity Biotech's Equity Average (Quarter) stood at $245500.0 in 2021, then surged by 807.74% to $2.2 million in 2022, then crashed by 1029.68% to -$20.7 million in 2023, then crashed by 48.48% to -$30.8 million in 2024, then crashed by 37.7% to -$42.4 million in 2025.
- Its Equity Average was -$42.4 million in Q2 2025, compared to -$30.8 million in Q4 2024 and -$27.9 million in Q3 2024.